LBRX LB Pharmaceuticals Inc Common Stock
Healthcare$28.31+0.00%OpenMarket Cap: $811.8M
As of 2026-05-26
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.10
P/S
0.00
EV/EBITDA
-10.59
DCF Value
$9.67
FCF Yield
-6.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-17.7%
ROA
-10.0%
ROIC
-12.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-19.1M | $— |
| Q4 null | $0.00 | $-11.5M | $— |
| FY null | $0.00 | $-25.2M | $— |
| Q3 null | $0.00 | $-3.6M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$39.50
Target (Median)
$38.50
Target Range
$36.00 - $45.00
1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
StifelBuy
2026-03-27StifelBuy
2025-12-11Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.38
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.